<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005639</url>
  </required_header>
  <id_info>
    <org_study_id>J9982</org_study_id>
    <secondary_id>U01CA070095</secondary_id>
    <secondary_id>R01CA075525</secondary_id>
    <secondary_id>P50CA058236</secondary_id>
    <secondary_id>P30CA006973</secondary_id>
    <secondary_id>CDR0000067799</secondary_id>
    <secondary_id>NCI-270</secondary_id>
    <secondary_id>99-12-03-02</secondary_id>
    <nct_id>NCT00005639</nct_id>
  </id_info>
  <brief_title>Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment</brief_title>
  <official_title>A Phase I Dose Escalation to Maximally Tolerated Dose Trial of 5-Azacytidine (5 AC, NSC 102816) in Combination With Sodium Phenylbutyrate (PB, NSC 657802) in Patients With Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: This phase I trial is studying the side effects and best dose of azacitidine plus
      phenylbutyrate in treating patients with advanced or metastatic solid tumors that have not
      responded to previous treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate the safety and toxicity of azacitidine plus phenylbutyrate in patients with
           refractory solid tumors.

        -  Determine the maximum tolerated dose of this treatment regimen where maximal gene
           reexpression occurs in these patients.

        -  Evaluate the pharmacokinetics of these drugs in these patients.

        -  Determine the minimally effective dose of azacitidine in combination with phenylbutyrate
           that elicits a biological or clinical response in these patients.

      OUTLINE: This is a dose escalation study.

      Patients receive azacitidine subcutaneously for 14-21 days and sodium phenylbutyrate IV
      continuously for 1-7 days. Treatment repeats every 35 days in the absence of disease
      progression or unacceptable toxicity.

      Cohorts of 3-6 patients receive escalating doses and durations of treatment with azacitidine
      and phenylbutyrate until the maximum tolerated dose (MTD) is determined. The MTD is defined
      as the dose preceding that at which 2 of 6 patients experience dose limiting toxicities.

      PROJECTED ACCRUAL: Approximately 3-50 patients will be accrued for this study within 12-18
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2000</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minimal Effective Dose (MED) of Azacitidine with Phenylbutyrate</measure>
    <time_frame>up to 6 months</time_frame>
    <description>MED (milligrams) of combined Azacitidine and Phenylbutyrate that results in clinical response, as defined by Standard World Health Organization (WHO) criteria and/or target inhibition.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity as assessed by number of participants experiencing adverse events Grade 3 or higher as defined by CTCAE v2.0</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Azacitidine combined with Phenylbutyrate as measured by maximal plasma concentration (Cmax)</measure>
    <time_frame>Up to 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gene-re-expression of epigenetic modulation in Peripheral Blood Mononuclear Cells (PBMC) as measured by change in Epstein-Barr Virus (EBV) viral load (number of copies per 1 million cells) after treatment with Azacitidine</measure>
    <time_frame>Change from baseline to up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Lymphoma</condition>
  <condition>Small Intestine Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Regimen A: 14-day 5-AC with intermittent phenylbutyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive low-dose regimen of 5-AC with intermittent phenylbutyrate 400 mg/m2/day by continuous intravenous (CIV) over 24 hours on Days 6 and 13. Each cycle lasts 35 days.
Cohort A1: 25 mg/m2/day subcutaneous (SC) Cohort A-1: 18.75 mg/m2/day SC Cohort A-2: 15 mg/m2/day SC Cohort A-3: 10 mg/m2/day SC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen B: 7-day 5-AC with sequential phenylbutyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive 5-AC 75mg/m2/day SC for 7 days, followed sequentially by two different doses of phenylbutyrate CIV starting on Day 8 and continuing for 7 days. Each cycle lasts 35 days
Cohort B1: Phenylbutyrate 200 mg/m2/day CIV Cohort B2: Phenylbutyrate 400 mg/m2/day CIV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regimen C: 21-day 5-AC with weekly phenylbutyrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive two different daily doses of 5-AC SC for 21 days and phenylbutyrate 400 mg/m2/day CIV over 24 hours once-per-week. Each cycle lasts 42 days.
Cohort C1: 5-AC 10mg/m2/day SC Cohort C2: 5-AC 12.5mg/m2/day SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azacitidine Injection</intervention_name>
    <description>subcutaneous injection (SC)</description>
    <arm_group_label>Regimen A: 14-day 5-AC with intermittent phenylbutyrate</arm_group_label>
    <arm_group_label>Regimen B: 7-day 5-AC with sequential phenylbutyrate</arm_group_label>
    <arm_group_label>Regimen C: 21-day 5-AC with weekly phenylbutyrate</arm_group_label>
    <other_name>AC</other_name>
    <other_name>5-AC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sodium phenylbutyrate</intervention_name>
    <description>continuous intravenous (CIV)</description>
    <arm_group_label>Regimen A: 14-day 5-AC with intermittent phenylbutyrate</arm_group_label>
    <arm_group_label>Regimen B: 7-day 5-AC with sequential phenylbutyrate</arm_group_label>
    <arm_group_label>Regimen C: 21-day 5-AC with weekly phenylbutyrate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed locally advanced or metastatic malignant
             solid tumor not amenable to curative therapy

               -  Lymphoma allowed

          -  Progressive disease

          -  Evaluable disease

          -  No CNS metastases by CT scan or MRI

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Hemoglobin at least 8 g/dL (may be achieved by transfusion)

          -  Absolute neutrophil count at least 1,500/mm^3

          -  Platelet count at least 100,000/mm^3

        Hepatic:

          -  Bilirubin no greater than 2 mg/dL (unless due to hemolysis or Gilbert's syndrome)

          -  SGOT and SGPT less than 2 times upper limit of normal

        Renal:

          -  Creatinine no greater than 2.0 mg/dL

        Other:

          -  No active infection

          -  HIV negative

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception for 2 weeks before, during, and 3
             months after study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  At least 4 weeks since prior adjuvant chemotherapy for advanced or metastatic disease
             and recovered

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  At least 4 weeks since prior radiotherapy and recovered

        Surgery:

          -  Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Carducci, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lin J, Gilbert J, Rudek MA, Zwiebel JA, Gore S, Jiemjit A, Zhao M, Baker SD, Ambinder RF, Herman JG, Donehower RC, Carducci MA. A phase I dose-finding study of 5-azacytidine in combination with sodium phenylbutyrate in patients with refractory solid tumors. Clin Cancer Res. 2009 Oct 1;15(19):6241-9. doi: 10.1158/1078-0432.CCR-09-0567. Epub 2009 Sep 29.</citation>
    <PMID>19789320</PMID>
  </results_reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>May 2, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 9, 2019</last_update_submitted>
  <last_update_submitted_qc>January 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>small intestine lymphoma</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Intestinal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
    <mesh_term>4-phenylbutyric acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

